Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer
Abstract Background Thrombocytosis is related to tumor stage and survival in ovarian cancer in addition to the common complications of malignant diseases, such as anemia and inflammation. The aim of our study was to clarify the precise prognostic impact of pretreatment thrombocytosis in epithelial o...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | Journal of Ovarian Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13048-020-00651-6 |
id |
doaj-e8754179f4094a5c8ffefe2f09df4ad1 |
---|---|
record_format |
Article |
spelling |
doaj-e8754179f4094a5c8ffefe2f09df4ad12020-11-25T02:38:22ZengBMCJournal of Ovarian Research1757-22152020-05-011311910.1186/s13048-020-00651-6Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancerSari Nakao0Takeo Minaguchi1Hiroya Itagaki2Yoshihiko Hosokawa3Ayumi Shikama4Nobutaka Tasaka5Azusa Akiyama6Hiroyuki Ochi7Koji Matsumoto8Toyomi Satoh9Department of Obstetrics and Gynecology, Faculty of Medicine, University of TsukubaDepartment of Obstetrics and Gynecology, Faculty of Medicine, University of TsukubaDepartment of Obstetrics and Gynecology, Faculty of Medicine, University of TsukubaDepartment of Obstetrics and Gynecology, Faculty of Medicine, University of TsukubaDepartment of Obstetrics and Gynecology, Faculty of Medicine, University of TsukubaDepartment of Obstetrics and Gynecology, Faculty of Medicine, University of TsukubaDepartment of Obstetrics and Gynecology, Faculty of Medicine, University of TsukubaDepartment of Obstetrics and Gynecology, Faculty of Medicine, University of TsukubaDepartment of Obstetrics and Gynecology, Showa University School of MedicineDepartment of Obstetrics and Gynecology, Faculty of Medicine, University of TsukubaAbstract Background Thrombocytosis is related to tumor stage and survival in ovarian cancer in addition to the common complications of malignant diseases, such as anemia and inflammation. The aim of our study was to clarify the precise prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer. Methods We retrospectively analyzed 280 consecutive patients who were treated for epithelial ovarian cancer at our institution between 2001 and 2011. Results Pretreatment thrombocytosis was observed in 18.9% of all patients and was associated with advanced FIGO stage, primary treatment, operation achievement, histologic subtype, microcytic hypochromic anemia (MHA), and nonmalignant inflammatory condition (P = 0.0018, 0.0028, 0.00050, 0.034, 0.00090 and 0.0022). In the patients who relapsed after primary adjuvant chemotherapy (n = 126), thrombocytosis was associated with a shorter treatment-free interval (TFI) (P = 0.0091). The univariate and multivariate analyses revealed that thrombocytosis was independently associated with TFI and MHA (P = 0.021 and 0.0091). Patients with thrombocytosis had worse progression-free survival (PFS) and overall survival (OS) than those without thrombocytosis (P < 0.0001 and < 0.0001). The multivariate analyses for prognostic factors demonstrated that thrombocytosis was significant for poor PFS and OS (P = 0.0050 and 0.022) independent of stage, histology, primary treatment, operation achievement, nonmalignant inflammatory condition and MHA. Conclusions The current findings indicate that the detrimental survival impact of pretreatment thrombocytosis in epithelial ovarian cancer may be independent of tumor extent but rather attributed to chemoresistance, further supporting the therapeutic potential of targeting thrombopoietic cytokines in the disease.http://link.springer.com/article/10.1186/s13048-020-00651-6ThrombocytosisOvarian cancerSurvival |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sari Nakao Takeo Minaguchi Hiroya Itagaki Yoshihiko Hosokawa Ayumi Shikama Nobutaka Tasaka Azusa Akiyama Hiroyuki Ochi Koji Matsumoto Toyomi Satoh |
spellingShingle |
Sari Nakao Takeo Minaguchi Hiroya Itagaki Yoshihiko Hosokawa Ayumi Shikama Nobutaka Tasaka Azusa Akiyama Hiroyuki Ochi Koji Matsumoto Toyomi Satoh Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer Journal of Ovarian Research Thrombocytosis Ovarian cancer Survival |
author_facet |
Sari Nakao Takeo Minaguchi Hiroya Itagaki Yoshihiko Hosokawa Ayumi Shikama Nobutaka Tasaka Azusa Akiyama Hiroyuki Ochi Koji Matsumoto Toyomi Satoh |
author_sort |
Sari Nakao |
title |
Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer |
title_short |
Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer |
title_full |
Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer |
title_fullStr |
Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer |
title_full_unstemmed |
Pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer |
title_sort |
pretreatment thrombocytosis as an independent predictive factor for chemoresistance and poor survival in epithelial ovarian cancer |
publisher |
BMC |
series |
Journal of Ovarian Research |
issn |
1757-2215 |
publishDate |
2020-05-01 |
description |
Abstract Background Thrombocytosis is related to tumor stage and survival in ovarian cancer in addition to the common complications of malignant diseases, such as anemia and inflammation. The aim of our study was to clarify the precise prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer. Methods We retrospectively analyzed 280 consecutive patients who were treated for epithelial ovarian cancer at our institution between 2001 and 2011. Results Pretreatment thrombocytosis was observed in 18.9% of all patients and was associated with advanced FIGO stage, primary treatment, operation achievement, histologic subtype, microcytic hypochromic anemia (MHA), and nonmalignant inflammatory condition (P = 0.0018, 0.0028, 0.00050, 0.034, 0.00090 and 0.0022). In the patients who relapsed after primary adjuvant chemotherapy (n = 126), thrombocytosis was associated with a shorter treatment-free interval (TFI) (P = 0.0091). The univariate and multivariate analyses revealed that thrombocytosis was independently associated with TFI and MHA (P = 0.021 and 0.0091). Patients with thrombocytosis had worse progression-free survival (PFS) and overall survival (OS) than those without thrombocytosis (P < 0.0001 and < 0.0001). The multivariate analyses for prognostic factors demonstrated that thrombocytosis was significant for poor PFS and OS (P = 0.0050 and 0.022) independent of stage, histology, primary treatment, operation achievement, nonmalignant inflammatory condition and MHA. Conclusions The current findings indicate that the detrimental survival impact of pretreatment thrombocytosis in epithelial ovarian cancer may be independent of tumor extent but rather attributed to chemoresistance, further supporting the therapeutic potential of targeting thrombopoietic cytokines in the disease. |
topic |
Thrombocytosis Ovarian cancer Survival |
url |
http://link.springer.com/article/10.1186/s13048-020-00651-6 |
work_keys_str_mv |
AT sarinakao pretreatmentthrombocytosisasanindependentpredictivefactorforchemoresistanceandpoorsurvivalinepithelialovariancancer AT takeominaguchi pretreatmentthrombocytosisasanindependentpredictivefactorforchemoresistanceandpoorsurvivalinepithelialovariancancer AT hiroyaitagaki pretreatmentthrombocytosisasanindependentpredictivefactorforchemoresistanceandpoorsurvivalinepithelialovariancancer AT yoshihikohosokawa pretreatmentthrombocytosisasanindependentpredictivefactorforchemoresistanceandpoorsurvivalinepithelialovariancancer AT ayumishikama pretreatmentthrombocytosisasanindependentpredictivefactorforchemoresistanceandpoorsurvivalinepithelialovariancancer AT nobutakatasaka pretreatmentthrombocytosisasanindependentpredictivefactorforchemoresistanceandpoorsurvivalinepithelialovariancancer AT azusaakiyama pretreatmentthrombocytosisasanindependentpredictivefactorforchemoresistanceandpoorsurvivalinepithelialovariancancer AT hiroyukiochi pretreatmentthrombocytosisasanindependentpredictivefactorforchemoresistanceandpoorsurvivalinepithelialovariancancer AT kojimatsumoto pretreatmentthrombocytosisasanindependentpredictivefactorforchemoresistanceandpoorsurvivalinepithelialovariancancer AT toyomisatoh pretreatmentthrombocytosisasanindependentpredictivefactorforchemoresistanceandpoorsurvivalinepithelialovariancancer |
_version_ |
1724791368550711296 |